We hypothesized that in patients with chronic obstructive pulmonary disease, loss of fat-free mass (FFM) and loss of bone mineral density (BMD) were related to (1 ) each other and may be clinically inapparent, (2 ) urinary markers of cellular and bone collagen protein breakdown, and (3 ) severity of lung disease. Eight-one patients and 38 healthy subjects underwent dual-energy X-ray absorptiometry to determine body composition and BMD. Urinary protein breakdown markers, inflammatory mediators, and their soluble receptors were determined. Thirty-three patients had a low fat-free mass index (kg/m 2 ), 17 of whom had a normal body mass index. Thirtytwo percent of patients (13% of healthy subjects) had osteoporosis at the hip or lumbar spine. The marker of cellular protein breakdown was elevated in patients and related to lung disease severity and body composition. The marker of bone collagen breakdown was greater in patients with osteoporosis. Inflammatory mediators were elevated in patients. Loss of FFM and loss of BMD were related, occurred commonly, and could be subclinical in patients with chronic obstructive pulmonary disease. Loss of both was greatest with severe lung disease. Increased excretion of cellular and bone collagen protein breakdown products in those with low FFM and BMD indicates a protein catabolic state in these patients.
systemic inflammation (13) (14) (15) (16) (17) . Alterations in body composition cause complications including impaired respiratory muscle function and loss of skeletal muscle mass with reduced force generation and endurance, which may contribute to the increased risk of fractures and disability, all of which become clinically relevant later in the natural history of COPD (4, (18) (19) (20) .
Body composition can be determined by various methods, with dual-energy X-ray absorptiometry being an established reliable, noninvasive, and quantitative option (21, 22) . Although giving body composition status, dual-energy X-ray absorptiometry does not indicate mechanisms associated with any changes detected. Isotopically determined protein turnover has been used in COPD, but is time consuming, expensive, and difficult to apply to large numbers of subjects (23) . Simpler methods include the measurement of urinary markers of protein breakdown. Excretion of pseudouridine (5-ribosyluracil, PSU), a modified nucleoside indicator of RNA and hence of cellular protein breakdown, is increased in disease states associated with chronic systemic inflammation (24, 25) . It is neither affected by diet, reutilized, nor degraded further (26) . Urinary excretion of N-telopeptides of collagen I (NTx), short polypeptide crosslinks, is a marker of bone collagen breakdown and has been used to monitor treatment responses in osteoporosis (27) (28) (29) .
We hypothesized that loss of FFM and loss of BMD are associated and may be clinically inapparent in COPD, and that both are related to the severity of lung disease. Second, we hypothesized that increased breakdown of cellular and bone protein would relate to FFM and BMD loss. To test these ideas we studied patients with a wide spectrum of severity of COPD and determined their FFM, BMD, and excretion of PSU and NTx, and compared them with healthy subjects. Some of the results of this study have been previously reported in the form of abstracts (30) (31) (32) .
METHODS

Patients
We recruited 81 patients previously diagnosed with COPD from among primary care, respiratory outpatients before pulmonary rehabilitation, when clinically stable: these patients had received no antibiotics or oral corticosteroids, or experienced any increase in respiratory symptoms, in the month before recruitment. Diagnosis was confirmed by spirometry according to GOLD (Global Initiative for Chronic Obstructive Pulmonary Disease) guidelines (33, 34) . We also studied 38 healthy subjects (HS). Exclusion criteria for all subjects included neoplastic disease or any disease with an inflammatory or metabolic component, cardiac failure, chronic oral corticosteroid treatment, or weight-lowering drugs. All subjects gave written, informed consent and the study had local research ethics committee approval.
Anthropometry and Lung Function
Height and weight (Seca; Vogel & Halke, Hamburg, Germany) were determined barefoot and in lightweight indoor clothing. The BMI was calculated and a low BMI was defined as 19.9 kg/m 2 or less (3, 16). FEV 1 , FVC, and their ratio (FEV 1 /FVC) were determined. Patients were subdivided into those with FEV 1 less than 50% predicted and those with FEV 1 greater than 50% predicted (33) .
Dual-energy X-ray Absorptiometry
Whole body composition and BMD of the lumbar spine and hip were determined with either a QDR 2000ϩ or Discovery bone densitometer (Hologic, Bedford, MA) with the patient supine. The total effective radiation dose was 5.2 Sv (35). Thirty patients underwent repeated measurements on the same day after repositioning. The coefficient of variation was less than 2.2% for lumbar spine and hip BMD, whole body bone mineral content, FM, and FFM. FM and FFM (excluding bone mineral content) were expressed as ratios to height squared to give indices, FMI and FFMI, (36, 37) . A low FFMI or FMI was defined as less than the lower 5th percentile of the healthy subjects for that sex (5) . The BMD is presented as absolute figures and as a T score (standard deviation [SD] from a young, sex-specific reference mean BMD) (38) .
Pseudouridine and N-telopeptides of Type I Collagen
A 20-ml second void urine sample was obtained. Urinary creatinine and PSU were analyzed by high-performance liquid chromatography (39) . Urine NTx concentration was measured by ELISA (Osteomark, Quidel, UK). Both PSU and NTx were expressed as a ratio to urinary creatinine concentration. To allow for differences in FFM, PSU and NTx were expressed as ratios to FFMI: PSU/FFMI (mol/mmol/kg/m 2 ) and NTx/FFMI (nmol/mmol/kg/m 2 ).
Inflammatory Mediators
Interleukin-6 (IL-6), tumor necrosis factor-␣ (TNF-␣), and its soluble receptors (TNF-␣ srI and srII) were measured by ELISA (R&D Systems Europe, Abingdon, UK) on batched samples with the assayist blind to subject identity (40) . Detection limits were as follows: IL-6 (0.039 pg/ml), TNF-␣ (0.12 pg/ml), TNF-␣ srI (0.77 pg/ml), and TNF-␣ srII (0.6 pg/ml). IL-6 sr was measured by an in-house ELISA using paired antibodies (detection limit, 0.034 ng/ml; R&D Systems Europe). The coefficient of variation was less than 10% for intra-and interassay variation for all assays.
Statistics
Data analysis was performed with the Statistical Package for the Social Sciences (SPSS, Chicago, IL), version 11.0. Results are presented as arithmetic or geometric (nonnormally distributed) means and 95% con- Definition of abbreviations: BMD ϭ bone mass density; BMI ϭ body mass index; FFM ϭ fat-free mass; FFMI ϭ fat-free mass index; ICS ϭ inhaled corticosteroid dose (betamethasone equivalent, g).
One patient failed to declare his oral maintenance dose of 5 mg of prednisolone until after analyses had been completed. His data have been included as his compliance with this is in doubt.
* p Ͻ 0.01. † p Ͻ 0.05. ‡ p Ͻ 0.05 for sex difference in height of the same subject group.
fidence interval. Analyses included the 2 test, independent t test, oneway analysis of variance with a post hoc Tukey test, Pearson correlation, and multiple regression. A p Ͻ 0.05 was considered significant.
RESULTS
Demographic data for all subjects are presented in Table 1 A normal BMI-normal FFMI occurred in 44 patients (22 male), a normal BMI-low FFMI was found for 17 patients (13 male), a low BMI-low FFMI occurred in 16 patients (7 male), and 4 patients (1 male) had a low BMI-normal FFMI. There was no age difference between groups ( Table 2) .
Fat-free Mass Index
The whole body FFMI was less in patients than in HS (Table 1) . Among patients, the whole body FFMI was less in the low BMIlow FFMI patients and in those with a normal BMI-low FFMI compared with the normal BMI-normal FFMI group (p Ͻ 0.001). There was no difference in FFMI between the normal BMI-low FFMI and low BMI-low FFMI groups ( Definition of abbreviations: BMD ϭ bone mass density; BMI ϭ body mass index; FFMI ϭ fat-free mass index; FMI ϭ fat mass index; NTx ϭ N-telopeptides of collagen I; PSU ϭ pseudouridine (5-ribosyl uracil).
* p Ͻ 0.05 compared with patients with normal BMI-normal FFMI. † p Ͻ 0.01 compared with patients with normal BMI-normal FFMI.
Fat Mass Index
The total FMI was lower in patients than in healthy subjects (Table 1) , but was not different between patients whose FEV 1 was greater or lesser than 50% predicted (p ϭ 0.102). Although maintaining a BMI greater than 19.9 kg/m 2 , patients with normal BMI-low FFMI had a significantly lower FMI than those with normal BMI-normal FFMI (Table 2) .
Bone Mineral Density
The total BMD at both the lumbar and hip regions of patients was less than for HS (both p Ͻ 0.001) ( Table 1) , as it was for individual lumbar sites (L1-L4) and hip sites (femoral neck, trochanter, and intertrochanteric region) (p Ͻ 0.02 for all). There were lower BMD and T scores for the total hip site in patients with low BMI-low FFMI or with normal BMI-low FFMI compared with normal BMI-normal FFMI patients. There was no difference between these subgroups for the total lumbar region ( Figure 1 and Table 2 ). The BMD was less at the hip in those with FEV 1 less than 50% predicted compared with those with milder disease (p ϭ 0.002), with no difference at the lumbar spine ( Figure 2) .
Using multiple regression analyses with total BMD at the lumbar and hip sites as the dependent variable, associations with FFMI, FMI, smoking pack-years, age, sex, IL-6, inhaled corticosteroid dose, and actual FEV 1 were explored among patients. At the hip site, only total FFMI (p Ͻ 0.001) revealed a significant effect on BMD, with overall adjusted r 2 ϭ 0.595. Similar relationships were found at the lumbar site BMD with FFMI (p ϭ 0.002), but not with the other variables (r 2 ϭ 0.334 for all variables). Among the HS, none of these variables had a significant effect on BMD, with adjusted r 2 ϭ 0.301 (hip) and r 2 ϭ 0.145 (lumbar region).
Osteoporosis/Osteopenia
For the HS, at the total lumbar site 5 (13.2%) had osteoporotic T scores (less than Ϫ2.5) and 10 (26.3%) had osteopenia (T score less than Ϫ1 but greater than Ϫ2.5) (38) . At the total hip site 2 had osteoporosis (5%) and 11 had osteopenia (28.9% Using age-and sex-specific reference ranges (Z score), 26 of the patients had an SD less than Ϫ1 for the total lumbar region, as did 28 for the total hip site, compared with 7 HS at the lumbar region and 2 HS at the hip region. There was no difference in the sex mix for those with a low Z score in either of the subject groups.
Pseudouridine/Fat-free Mass Index
The PSU/FFMI was greater in patients than in HS (Table 3) , and was greater in those with an FEV 1 less than 50% predicted compared with an FEV 1 exceeding 50% predicted (p ϭ 0.02) Bone mineral density at the lumbar spine and hip regions in patients according to lung function and compared with healthy subjects. Data are shown as means with 95% confidence intervals. Open columns, healthy; solid columns, patients with FEV 1 greater than 50% predicted; gray columns, patients with FEV 1 less than 50% predicted. *Significant difference (p Ͻ 0.05).
( Figure 5 ). The PSU/FFMI was greater in low BMI-low FFMI patients than in normal BMI-normal FFMI patients (p ϭ 0.047) ( Table 2 ). Among patients, the PSU/FFMI was inversely related to the actual FEV 1 (r ϭ Ϫ0.403, p Ͻ 0.001).
N-telopeptides of Type I Collagen/Fat-free Mass Index
NTx was not different between patients and HS or between patients on the basis of body composition, but was greater in those with severe lung disease (Table 3 and Figure 5 ). The NTx/ FFMI inversely related to actual FEV 1 (r ϭ Ϫ0.33, p ϭ 0.003) in patients. The NTx/FFMI was greater in patients with osteoporosis at the lumbar spine Definition of abbreviations: FFMI ϭ fat-free mass index; IL-6 ϭ interleukin-6; NTx ϭ N-telopeptides of collagen I; PSU ϭ pseudouridine (5-ribosyl uracil); sr ϭ soluble receptor; TNF-␣ ϭ tumor necrosis factor-␣.
All data are expressed as geometric means (95% CI). * p Ͻ 0.05. † p Ͻ 0.01.
greater in patients than in HS ( 
DISCUSSION
In patients with COPD encompassing a wide spectrum of disease severity we found a relationship between loss of FFM and BMD. In addition, urinary markers of cellular and bone collagen protein breakdown were related, further supporting the association between loss of FFM and BMD. In the context of COPD the losses from these two protein-rich body compartments may be linked by common mechanisms leading to proteolysis, which adds to the primary impacts of the lung disease leading to loss of skeletal muscle mass, excess bone loss, and progressive disability. Within our group of patients 21% had "hidden" loss of FFM with a normal BMI, similar to other studies (4, 5, 16) . This subgroup of patients resembled those with low BMI-low FFM, with no difference between their FFMI or their T scores at the Figure 5 . Pseudouridine (PSU/FFMI) and N-telopeptides of type I collagen (NTx/FFMI) in healthy subjects and patients according to severity of lung disease. Open columns, healthy; solid columns, patients with FEV 1 greater than 50% predicted; gray columns, patients with FEV 1 less than 50% predicted. Data are presented as geometric means with 95% confidence intervals. *p Ͻ 0.05. hip, indicating a high level of subclinical bone disease, with 15 of these 17 having either osteoporosis or osteopenia. In the patients with normal BMI-low FFM there was preferential FFM loss, with some FM loss despite maintaining a normal BMI. These findings emphasize the added value and need for anthropometric assessment rather than simple weight, height, and BMI (4, 5, 16) . The FFMI was related to the severity of lung disease based on FEV 1 and to circulating IL-6 concentrations. The increased PSU in those with low FFMI probably reflects breakdown of cellular tissues, such as skeletal muscle, leading to cachexia and physical disability. This could be considered a maladaptive response in individuals with already depleted FFM, but such interpretation needs to be made cautiously, as PSU is a measure only of breakdown. Protein turnover studies in COPD suggest both an increase in protein synthesis and breakdown, with the latter predominating (23) . Hence, we chose to measure PSU as an indicator of the prominent process likely to be occurring in patients with COPD and loss of FFM.
We confirmed previous reports of a greater degree of systemic inflammation in our patients (16, 41) . Increased concentrations of circulating IL-6 and TNF-␣ in patients may reflect a potential pathophysiological mechanism, as in animal and in vitro studies both are associated with skeletal muscle atrophy and increased protein breakdown (42) (43) (44) (45) (46) . Increased release of TNF-␣ by mononuclear cells has been reported in weight-losing patients with COPD (47) . However, we found no relationships between TNF-␣ and its soluble receptors or IL-6 sr and altered body composition in this study, which may reflect the wide range of lung disease severity we studied in this cross-sectional review, in which the weight stability status of our patients was not determined (16, 47) . Despite our exclusion criteria, other confounding influences may have occurred as a result of inapparent inflammatory disease.
High levels of bone disease occurred in the patients, with more than 80% meeting the definition of osteoporosis or osteopenia, which had not been previously diagnosed. One-third of our patients had osteoporosis, compared with 13% of the HS, which agrees with the reported high levels of serious bone disease in COPD and is similar to reports of 36% osteoporosis and 56% of patients with bone loss in studies using mixed disease groups and Z scores to define bone loss (6, 48, 49) . Linkage between loss of FFM and bone disease may indicate associated mechanisms of loss and our findings of increased protein breakdown in the cellular and bone extracellular matrix compartments support this view. A key feature of our patients was the stronger association of both lung disease and the link between FFM and bone loss at the hip compared with the lumbar spine. The lack of separation of lumbar BMD and T score between the patient groups according to body composition or airway obstruction may be due to the confounding effect of degenerative spine disease and loss of vertebral height leading to an apparently greater BMD in the presence of osteoporosis. As with loss of FFM, systemic inflammation may have an association with loss of bone with similar relationships reported in other chronic diseases with depletion of FFM (50) (51) (52) . In vitro, both IL-6 and TNF-␣ stimulate osteoclasts and increase bone resorption (53) (54) (55) (56) (57) . Performing dual-energy X-ray absorptiometry scans on every patient with COPD is not a practical option, but simple markers including anthropometry (such as skinfold anthropometry and bioelectrical impedance) may assist in the identification of patients who have FFM loss and who subsequently are at greater risk of bone disease in larger community-based populations (58) .
Limitations of the Study
Definitions of the severity of lung disease, FFM, and osteoporosis may seem arbitrary and could impose limitations on group analyses. To define the severity of lung disease we opted for subdivision based on less or greater than 50% predicted FEV 1 , a division in both the GOLD and NICE (National Institute for Clinical Excellence) guidelines (33, 59) . There is no consensus on the definition of low FFM and various criteria have been used (4, 5, 16, 60) . In this study low FFMI was defined as less than the lower 5th percentile of the HS to obtain an abnormal group with environmental and lifestyle factors similar to those of the local population. There is no recognized definition of osteoporosis in men, but it is generally accepted to use the same definition as for postmenopausal women (61) . In this observational study of altered body composition in COPD we did not explore the possible contribution of physical inactivity and catabolic/anabolic hormone balance to FFM and bone loss, so few conclusions as to causative mechanisms can be drawn; however, our findings suggest future studies would be worthwhile to define such interactive processes (17, 62, 63) . It was not possible to obtain a cumulative dose of inhaled corticosteroid usage for all patients. Although more than half of the patients were taking inhaled corticosteroids, only 14 were taking doses greater than 1,000 g/day, which may have had an influence on bone loss, although this remains unclear and is difficult to separate from other influences, not the least being the more severe lung disease for which it is prescribed (59, 64).
Conclusions
We have demonstrated that loss of BMD and FFM are related and are associated with the severity of lung disease and with urinary markers of protein breakdown. Even in milder COPD, there was a high prevalence of osteoporosis that was not suspected on clinical grounds. With the predicted worldwide increase in COPD and the personal, clinical, and fiscal implications of progressive disability and secondary complications, such as hip and spinal fractures, the identification of patients with undetected bone disease and a high risk of osteoporosis is of considerable importance. Although many of the complications of COPD are associated with increasingly severe lung disease, this study extends earlier work by demonstrating high levels of clinically inapparent bone loss occurring in patients with milder degrees of lung disease severity.
Conflict of Interest Statement : C.E.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; A.A.I. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; K.M.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; R.J.P. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; P.H.E. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; M.D.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; L.S.N. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; W.D.E. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; T.L.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; D.J.S. has participated as a speaker in postgraduate meetings organized and financed by AstraZeneca (AZ) and GlaxoSmithKline (GSK) and has received sponsorship to attend international and national conferences from AZ, 
